0.00Open0.00Pre Close0 Volume0 Open Interest45.00Strike Price0.00Turnover1057.53%IV-42.38%PremiumNov 29, 2024Expiry Date33.10Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9788Delta0.0022Gamma2.35Leverage Ratio-1.9466Theta0.0003Rho2.30Eff Leverage0.0011Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet